Clinical Trials Browser

Phase 1/2 × Multiple Myeloma × reolysin × Clear all

NCT05514990 2026-05-13

Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial

Phase 1/2 Active not recruiting

Multiple Myeloma